Tandem Diabetes Care Inc. has announced a new partnership with Abbott to enhance diabetes management technology. The collaboration integrates Tandem's t:slim X2™ insulin pump, equipped with Control-IQ+ automated insulin delivery technology, with Abbott's FreeStyle Libre® 3 Plus continuous glucose monitoring sensor. This integration aims to offer personalized solutions for people living with diabetes by allowing the insulin pump to receive automatic glucose readings every minute from the sensor. The partnership is set to expand the availability of this integrated system in the United States starting the second half of 2025, with plans to extend access to international markets later this year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.